Choice of antiretroviral drugs for continued treatment scale‐up in a public health approach: what more do we need to know?

Introduction There have been several important developments in antiretroviral treatment in the past two years. Randomized clinical trials have been conducted to evaluate a lower dose of efavirenz (400 mg once daily). Integrase inhibitors such as dolutegravir have been approved for first‐line treatme...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Marco Vitoria, Andrew M Hill, Nathan P Ford, Meg Doherty, Saye H Khoo, Anton L Pozniak
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2016-01-01
Saila:	Journal of the International AIDS Society
Gaiak:	antiretroviral treatment Universal Access nucleoside analogues integrase inhibitors protease inhibitors non‐nucleosides
Sarrera elektronikoa:	https://doi.org/10.7448/IAS.19.1.20504
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!